$ABOS
Acumen Pharmaceuticals, Inc. Stock $abos

$abos Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000157688523000025 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.345M	$4.422M	$3.221M
YoY Change	40.61%	37.29%	165.1%
% of Gross Profit
Research & Development	$9.133M	$8.713M	$5.985M
YoY Change	24.75%	45.58%	132.16%
% of Gross Profit
Depreciation & Amortization	$15.00K	$14.00K	$4.000K
YoY Change	150.0%	250.0%
% of Gross Profit
Operating Expenses	$13.48M	$13.14M	$9.206M
YoY Change	29.46%	42.68%	142.71%
Operating Profit	-$13.48M	-$13.14M	-$9.206M
YoY Change	29.46%	42.68%
Interest Expense	$1.884M	$1.832M	$76.00K
YoY Change	624.62%	2310.53%	1800.0%
% of Operating Profit
Other Income/Expense, Net	$1.868M	$1.828M	$1.000K
YoY Change	618.46%	182700.0%	-100.0%
Pretax Income	-$11.61M	-$11.31M	-$9.129M
YoY Change	14.37%	23.86%	-66.19%
Income Tax
% Of Pretax Income
Net Earnings	-$11.61M	-$11.31M	-$9.129M
YoY Change	14.37%	23.86%	-66.19%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.28	-$0.28	-$0.23
Diluted Earnings Per Share	-$0.28	-$0.28	-$225.6K
COMMON SHARES
Basic Shares Outstanding	41.03M shares	41.03M shares	40.47M shares
Diluted Shares Outstanding	41.03M shares	41.03M shares	40.47M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$144.9M	$140.4M	$189.1M
YoY Change	-23.71%	-25.74%	356.66%
Cash & Equivalents	$77.25M	$78.00M	$108.8M
Short-Term Investments	$67.63M	$62.41M	$80.33M
Other Short-Term Assets	$208.0K	$294.0K	$3.008M
YoY Change	-81.79%	-90.23%	412.44%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$149.5M	$144.0M	$192.1M
YoY Change	-21.73%	-25.02%	356.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$136.0K	$151.0K	$252.0K
YoY Change	20.35%	-40.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$27.31M	$43.42M	$27.66M
YoY Change	36.55%	56.99%
Other Assets	$208.0K	$195.0K	$79.00K
YoY Change	96.23%	146.84%	-70.74%
Total Long-Term Assets	$27.87M	$43.83M	$27.99M
YoY Change	35.11%	56.6%	10266.3%
TOTAL ASSETS
Total Short-Term Assets	$149.5M	$144.0M	$192.1M
Total Long-Term Assets	$27.87M	$43.83M	$27.99M
Total Assets	$177.4M	$187.9M	$220.1M
YoY Change	-16.19%	-14.64%	419.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.026M	$762.0K	$1.219M
YoY Change	18.48%	-37.49%	32.79%
Accrued Expenses	$2.374M	$7.923M	$2.618M
YoY Change	-28.56%	202.64%	69.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.531M	$8.779M	$3.936M
YoY Change	66.17%	123.04%	-87.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities			$62.00K
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$62.00K
YoY Change	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.531M	$8.779M	$3.936M
Total Long-Term Liabilities	$0.00	$0.00	$62.00K
Total Liabilities	$8.531M	$8.779M	$3.998M
YoY Change	65.36%	119.58%	-87.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$193.3M	-$181.7M
YoY Change	31.59%
Common Stock	$4.000K	$4.000K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$168.9M	$179.1M	$216.1M
YoY Change
Total Liabilities & Shareholders Equity	$177.4M	$187.9M	$220.1M
YoY Change	-16.19%	-14.64%	419.4%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$11.61M	-$11.31M	-$9.129M
YoY Change	14.37%	23.86%	-66.19%
Depreciation, Depletion And Amortization	$15.00K	$14.00K	$4.000K
YoY Change	150.0%	250.0%
Cash From Operating Activities	-$11.67M	-$10.18M	-$8.299M
YoY Change	80.43%	22.61%	250.17%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$9.000K
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$11.06M	-$41.93M	-$5.090M
YoY Change	25.43%	723.71%
Cash From Investing Activities	$11.06M	-$41.93M	-$5.099M
YoY Change	25.94%	722.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-145.0K	$0.00
YoY Change	935.71%
NET CHANGE
Cash From Operating Activities	-11.67M	-$10.18M	-8.299M
Cash From Investing Activities	11.06M	-$41.93M	-5.099M
Cash From Financing Activities	-145.0K	$0.00
Net Change In Cash	-751.0K	-$52.10M	-13.40M
YoY Change	-132.61%	288.88%	465.32%
FREE CASH FLOW
Cash From Operating Activities	-$11.67M	-$10.18M	-$8.299M
Capital Expenditures	$0.00	$0.00	-$9.000K
Free Cash Flow	-$11.67M	-$10.18M	-$8.290M
YoY Change	81.44%	22.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001576885
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40551
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Acumen Pharmaceuticals, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	36-4108129
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	427 Park St.
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Charlottesville
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	22902
CY2023Q1	dei	City Area Code CityAreaCode	434
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	297-1000
CY2023Q1	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	ABOS
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41025062	shares
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77999000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130101000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	62410000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	47504000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3623000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2724000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	144032000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	180329000	usd
CY2023Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	43419000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	15837000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	151000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	165000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	67000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	105000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	195000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	151000	usd
CY2023Q1	us-gaap	Assets Assets	187864000	usd
CY2022Q4	us-gaap	Assets Assets	196587000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	762000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1640000	usd
CY2023Q1	abos	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	5203000	usd
CY2022Q4	abos	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	2717000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2747000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3350000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	67000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	105000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8779000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7812000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	8779000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7812000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41025062	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41025062	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41025062	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41025062	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	361339000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	359949000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-181734000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-170427000	usd
CY2023Q1	us-gaap	Aoci Before Tax Attributable To Parent AociBeforeTaxAttributableToParent	-524000	usd
CY2022Q4	us-gaap	Aoci Before Tax Attributable To Parent AociBeforeTaxAttributableToParent	-751000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	179085000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	188775000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	187864000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	196587000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8713000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5985000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4422000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3221000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	13135000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	9206000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13135000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9206000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1832000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	76000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1828000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	77000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11307000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-9129000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	227000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-583000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11080000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9712000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41025062	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41025062	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40473270	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40473270	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	188775000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	227000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1390000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11307000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	179085000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	225183000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-583000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	618000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-9129000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	216089000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11307000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-9129000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	14000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	4000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1390000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	618000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	334000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-216000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	38000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	33000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	899000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1416000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	44000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	65000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-878000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	121000	usd
CY2023Q1	abos	Increase Decrease In Accrued Clinical Trial Expenses IncreaseDecreaseInAccruedClinicalTrialExpenses	2486000	usd
CY2022Q1	abos	Increase Decrease In Accrued Clinical Trial Expenses IncreaseDecreaseInAccruedClinicalTrialExpenses	281000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-38000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-32000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-603000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1762000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10175000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8299000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	52131000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9090000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	10204000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	4000000	usd
CY2023Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	0	usd
CY2022Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	9000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-41927000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5099000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-52102000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-13398000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130101000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	122162000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77999000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108764000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acumen Pharmaceuticals, Inc. (“Acumen” or the “Company”) was incorporated in 1996 in the state of Delaware. Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what the Company believes to be a key underlying cause of Alzheimer’s disease (“AD”). Alzheimer’s disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death. The Company’s scientific founders pioneered research on soluble amyloid-beta oligomers (“AßOs”), which are globular assemblies of the amyloid-beta (“Aß”) peptide that are distinct from Aß monomers and amyloid plaques. Based on decades of research and supporting evidence, AßOs have gained increasing scientific acceptance as primary toxins involved in the initiation and propagation of AD pathology. The Company is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, through a clinical proof of mechanism trial in “early AD” patients (patients with mild cognitive impairment or mild dementia due to Alzheimer’s pathology). ACU193 is a recombinant humanized immunoglobulin gamma 2 (“IgG2”) monoclonal antibody (“mAb”) that was designed to selectively target AßOs, has demonstrated functional and protective effects in in vitro assays, and has demonstrated in vivo safety and pharmacologic activity in multiple animal species, including transgenic mouse models for AD. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the uncertainty of whether the Company’s intellectual property will develop into successful commercial products. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of March 31, 2023 and December 31, 2022, the Company had an accumulated deficit of $181.7 million and $170.4 million, respectively, and working capital of $135.3 million and $172.5 million, respectively. Management believes that the Company has sufficient cash to continue operating activities for beyond 12 months from issuance of these condensed financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future capital requirements will depend upon many factors, including the timing and extent of spending on research and development and market acceptance of the Company’s products. The Company expects that it will need to obtain additional financing to complete clinical trials and launch and commercialize any product candidates for which it receives regulatory approval. Until such time, if ever, the Company can generate revenue sufficient to achieve profitability, the Company expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. There can be no assurance that such financing will be available on terms acceptable to the Company, or at all. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation of other preferences that adversely affect the rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. The Company may be required to delay, limit, reduce or terminate its product discovery and development activities or future commercialization efforts. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initiated a Phase 1 clinical trial of ACU193 in the second quarter of 2021, which the Company named “INTERCEPT-AD.” This trial enrolled 65 patients with “early AD.” INTERCEPT-AD is a U.S.-based, multi-center, randomized, double-blind, placebo-controlled clinical trial with overlapping single ascending dose and multiple ascending dose cohorts evaluating patients with early AD.</span></div>
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-181700000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-170400000	usd
CY2023Q1	abos	Working Capital WorkingCapital	135300000	usd
CY2022Q4	abos	Working Capital WorkingCapital	172500000	usd
CY2023Q1	abos	Number Of Patients Enrolled In Trial NumberOfPatientsEnrolledInTrial	65	patient
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements, as well as the reported amounts of expenses during the reporting periods. These estimates and assumptions are based on the Company’s historical experience, and on various other factors that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. </span></div>Actual results may differ from these estimates under different assumptions or conditions. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. Accrued clinical trial expenses are presented as a separate line on the statements of cash flows, whereas these accrued expenses were previously included in accrued expenses and other current liabilities. This reclassification had no effect on the reported results of operations.
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	62872000	usd
CY2023Q1	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	6000	usd
CY2023Q1	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	468000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	62410000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	43481000	usd
CY2023Q1	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	41000	usd
CY2023Q1	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	103000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	43419000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	106353000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	47000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	571000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	105829000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	48212000	usd
CY2022Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	0	usd
CY2022Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	708000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	47504000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	15880000	usd
CY2022Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	0	usd
CY2022Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	43000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	15837000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	64092000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	751000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	63341000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	59394000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	168000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	23755000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	403000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	83149000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	571000	usd
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	32541000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	65000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	30800000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	686000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	63341000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	751000	usd
CY2023Q1	abos	Debt Securities Available For Sale Noncurrent Term DebtSecuritiesAvailableForSaleNoncurrentTerm	P2Y
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	180128000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	192441000	usd
CY2023Q1	abos	Prepaid Raw Materials Current PrepaidRawMaterialsCurrent	1391000	usd
CY2022Q4	abos	Prepaid Raw Materials Current PrepaidRawMaterialsCurrent	199000	usd
CY2023Q1	abos	Research And Development Service Agreements Current ResearchAndDevelopmentServiceAgreementsCurrent	1132000	usd
CY2022Q4	abos	Research And Development Service Agreements Current ResearchAndDevelopmentServiceAgreementsCurrent	1077000	usd
CY2023Q1	abos	Prepaid Insurance Current PrepaidInsuranceCurrent	556000	usd
CY2022Q4	abos	Prepaid Insurance Current PrepaidInsuranceCurrent	1106000	usd
CY2023Q1	abos	Dues And Subscriptions Current DuesAndSubscriptionsCurrent	250000	usd
CY2022Q4	abos	Dues And Subscriptions Current DuesAndSubscriptionsCurrent	105000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	294000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	237000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3623000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2724000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1628000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2008000	usd
CY2023Q1	abos	Research And Development Liability Current ResearchAndDevelopmentLiabilityCurrent	829000	usd
CY2022Q4	abos	Research And Development Liability Current ResearchAndDevelopmentLiabilityCurrent	1211000	usd
CY2023Q1	abos	Legal Liability Current LegalLiabilityCurrent	190000	usd
CY2022Q4	abos	Legal Liability Current LegalLiabilityCurrent	0	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	0	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	94000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	131000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2747000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3350000	usd
CY2023Q1	abos	Common Stock And Preferred Stock Shares Authorized CommonStockAndPreferredStockSharesAuthorized	310000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	abos	Common Stock Number Of Voting Rights CommonStockNumberOfVotingRights	1	votingright
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1390000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	618000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.52
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.87
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5610893	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.36
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1628000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.96
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7238893	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.94
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	9805000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2769265	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.56
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y2M12D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	6446000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7567393	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4922019	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001576885-23-000025-index-headers.html	Edgar Link	pending
0001576885-23-000025-index.html	Edgar Link	pending
0001576885-23-000025.txt	Edgar Link	pending
0001576885-23-000025-xbrl.zip	Edgar Link	pending
abos-20230331.htm	Edgar Link	pending
abos-20230331.xsd	Edgar Link	pending
abos-20230331x10qxexx311.htm	Edgar Link	pending
abos-20230331x10qxexx312.htm	Edgar Link	pending
abos-20230331x10qxexx321.htm	Edgar Link	pending
abos-20230331x10qxexx322.htm	Edgar Link	pending
abos-20230331_cal.xml	Edgar Link	unprocessable
abos-20230331_def.xml	Edgar Link	unprocessable
abos-20230331_pre.xml	Edgar Link	unprocessable
abos-20230331_lab.xml	Edgar Link	unprocessable
abos-20230331_htm.xml	Edgar Link	completed
acumen_-xamendedxandxres.htm	Edgar Link	pending
acumen_-xamendedxandxres001.jpg	Edgar Link	pending
acumen_-xamendedxandxres002.jpg	Edgar Link	pending
acumen_-xamendedxandxres003.jpg	Edgar Link	pending
acumen_-xamendedxandxres004.jpg	Edgar Link	pending
acumen_-xamendedxandxres005.jpg	Edgar Link	pending
acumen_-xamendedxandxres006.jpg	Edgar Link	pending
acumen_-xamendedxandxres007.jpg	Edgar Link	pending
acumen_-xamendedxandxres008.jpg	Edgar Link	pending
acumen_-xamendedxandxres009.jpg	Edgar Link	pending
acumen_-xamendedxandxres010.jpg	Edgar Link	pending
acumen_-xamendedxandxres011.jpg	Edgar Link	pending
acumen_-xamendedxandxres012.jpg	Edgar Link	pending
acumen_-xamendedxandxres013.jpg	Edgar Link	pending
acumen_-xamendedxandxres014.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABOS
Acumen Pharmaceuticals, Inc. Stock $abos

2023 Q2 Form 10-Q Financial Statement

#000157688523000025 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABOS Acumen Pharmaceuticals, Inc. Stock $abos

2023 Q2 Form 10-Q Financial Statement

#000157688523000025 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABOS
Acumen Pharmaceuticals, Inc. Stock $abos